search
Back to results

Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis (DrNoha-ICU)

Primary Purpose

Major Trauma, Sepsis

Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
oral lactobacillus probiotics plus intramuscular cholecalciferol
intravenous vitamin C plus thiamine
Sponsored by
Mansoura University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Major Trauma

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult trauma patients admitted to ICU within 24 hours from trauma onset with injury severity score (ISS) ≥ 16 will be recruited after obtaining informed consent

Exclusion Criteria:

  • • Patients admitted to ICU after time exceeding 24 hours from trauma onset.

    • Patients whose age is less than 18 years.
    • Pregnant female.
    • Breast feeding women.
    • Arrest within 24 hours of admission.
    • Immune deficiency or administration of immune suppressant drugs.
    • Serum calcium greater than or equal to 10 mg/dl or phosphate greater than or equal 6 mg/dl.
    • History of primary parathyroid disease.
    • Metabolic bone disease.
    • Sarcoidosis.
    • End stage renal disease.
    • receiving intermittent renal replacement therapy (RRT).
    • Failure of enteral feeding or any contraindication to enteral administration.
    • Obesity , body mass index (BMI > 35 kg/m2)
    • Known contraindication to vitamin C or thiamine (oxalate nephropathy or known glucose-6-phosphate dehydrogenase deficiency)

Sites / Locations

  • Mansoura University-Emergency hospital-ICU

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

No Intervention

Active Comparator

Active Comparator

Arm Label

Low risk group

High risk control

High risk DP

High risk CB

Arm Description

no specific treatment will be given

no specific treatment will be given

patients will receive one intramuscular (IM) injection of 400,000 IU of cholecalciferol on day- 1 Also, starting from day 1 and till day 6 (for consequential 6 days), patients will receive lactobacillus probiotics (10 billion colony forming unit) in a dose of 6 sachets per day

Patients will receive vitamin C plus thiamine starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours

Outcomes

Primary Outcome Measures

Acute Physiology and Chronic Health Evaluation II (APACHE II) score
minim 0 maximum 71 Increasing score is associated with increasing risk of ICU mortality

Secondary Outcome Measures

Sequential Organ Failure Assessment (SOFA) score
minim 0 maximum 24 The acute increase of 2 or more in SOFA points indicates sepsis
Monocyte chemo attractant protein 1 (MCP-1)
Optimum cut-off value of MCP-1 for prediction of sepsis in severe trauma ICU patients is 240.7 pg/ml The decrease in its level indicates less inflammatory response and better patient out comes

Full Information

First Posted
December 30, 2019
Last Updated
October 7, 2021
Sponsor
Mansoura University
search

1. Study Identification

Unique Protocol Identification Number
NCT04216459
Brief Title
Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis
Acronym
DrNoha-ICU
Official Title
Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
February 18, 2020 (Actual)
Primary Completion Date
November 30, 2020 (Actual)
Study Completion Date
October 4, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mansoura University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The occurrence of sepsis in trauma patients is a very serious complication. Identifying trauma patients at high risk of sepsis was not revealed in the latest surviving sepsis campaign in 2016. Several biomarkers have been proposed for early prediction of sepsis in trauma patients as leukocyte anti sedimentation rate (LAR) and the proinflammatory cytokine monocyte chemo attractant protein-1 (MCP-1). Sepsis prophylaxis before occurrence of multi-organ failure still represents a major challenge. Vitamin D and probiotics have antimicrobial, anti-inflammatory and gut microbiota immune modulatory properties.Little is known about the effect of vitamin D and probiotics co-supplementation on the inflammatory response in trauma patients at high risk of sepsis. Another promising strategy is the use of vitamin C in addition to thiamine. Trauma is associated with increased oxidative stress and vitamin C deficiency. High dose vitamin C is required to restore oxidant-antioxidant balance. Vitamin C and thiamine have shown promising results in treatment of sepsis. Vitamin C possesses anti-inflammatory, endothelial protective and anti-microbial effects. Thiamine is the precursor of thiamine pyrophosphate (TPP), a key enzyme in Krebs cycle.
Detailed Description
This study will investigate effect of vitamin D and probiotics versus Vitamin C and thiamine on inflammatory response (represented by change in MCP-1 level), Sequential Organ Failure Assessment (SOFA) Score and Acute Physiology and Chronic Health Evaluation II (APACHE II) in trauma patients at high risk of sepsis. Secondary goal is to assess if the predictive ability of MCP-1 plus LAR to determine high risk of sepsis in major trauma intensive care patients and if there is correlation between LAR and MCP-1.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Trauma, Sepsis

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
112 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Low risk group
Arm Type
No Intervention
Arm Description
no specific treatment will be given
Arm Title
High risk control
Arm Type
No Intervention
Arm Description
no specific treatment will be given
Arm Title
High risk DP
Arm Type
Active Comparator
Arm Description
patients will receive one intramuscular (IM) injection of 400,000 IU of cholecalciferol on day- 1 Also, starting from day 1 and till day 6 (for consequential 6 days), patients will receive lactobacillus probiotics (10 billion colony forming unit) in a dose of 6 sachets per day
Arm Title
High risk CB
Arm Type
Active Comparator
Arm Description
Patients will receive vitamin C plus thiamine starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
Intervention Type
Drug
Intervention Name(s)
oral lactobacillus probiotics plus intramuscular cholecalciferol
Intervention Description
According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR < 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement
Intervention Type
Drug
Intervention Name(s)
intravenous vitamin C plus thiamine
Intervention Description
starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
Primary Outcome Measure Information:
Title
Acute Physiology and Chronic Health Evaluation II (APACHE II) score
Description
minim 0 maximum 71 Increasing score is associated with increasing risk of ICU mortality
Time Frame
0n the Day 0-Day 6 from onset of trauma
Secondary Outcome Measure Information:
Title
Sequential Organ Failure Assessment (SOFA) score
Description
minim 0 maximum 24 The acute increase of 2 or more in SOFA points indicates sepsis
Time Frame
0n the Day 0-Day 6 from onset of trauma
Title
Monocyte chemo attractant protein 1 (MCP-1)
Description
Optimum cut-off value of MCP-1 for prediction of sepsis in severe trauma ICU patients is 240.7 pg/ml The decrease in its level indicates less inflammatory response and better patient out comes
Time Frame
0n the Day 0-Day 6 from onset of trauma

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult trauma patients admitted to ICU within 24 hours from trauma onset with injury severity score (ISS) ≥ 16 will be recruited after obtaining informed consent Exclusion Criteria: • Patients admitted to ICU after time exceeding 24 hours from trauma onset. Patients whose age is less than 18 years. Pregnant female. Breast feeding women. Arrest within 24 hours of admission. Immune deficiency or administration of immune suppressant drugs. Serum calcium greater than or equal to 10 mg/dl or phosphate greater than or equal 6 mg/dl. History of primary parathyroid disease. Metabolic bone disease. Sarcoidosis. End stage renal disease. receiving intermittent renal replacement therapy (RRT). Failure of enteral feeding or any contraindication to enteral administration. Obesity , body mass index (BMI > 35 kg/m2) Known contraindication to vitamin C or thiamine (oxalate nephropathy or known glucose-6-phosphate dehydrogenase deficiency)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maha Ahmed Abozeid, MD
Organizational Affiliation
Faculty of Medicine - Mansoura University
Official's Role
Study Director
Facility Information:
Facility Name
Mansoura University-Emergency hospital-ICU
City
Mansoura
Country
Egypt

12. IPD Sharing Statement

Citations:
PubMed Identifier
34912231
Citation
Kamel NA, Soliman MM, Abo-Zeid MA, Shaaban MI. Effect of Anti-Inflammatory and Antimicrobial Cosupplementations on Sepsis Prevention in Critically Ill Trauma Patients at High Risk for Sepsis. Front Pharmacol. 2021 Nov 29;12:792741. doi: 10.3389/fphar.2021.792741. eCollection 2021.
Results Reference
derived

Learn more about this trial

Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis

We'll reach out to this number within 24 hrs